Full-Time

Human Resources Manager / Senior Manager

Bachem

Bachem

1,001-5,000 employees

Develops and manufactures peptides and oligonucleotides

Compensation Overview

$113.5k - $170.9k/yr

+ Bonus

Carson, CA, USA

In Person

Category
People & HR (1)
Required Skills
Human Resources Information System (HRIS)
Requirements
  • Bachelor's degree in Human Resources, Business Administration, Organizational Development, or related field
  • Master's degree in Human Resources, Business Administration, Organizational Development, or related field (preferred)
  • 10+ years of progressive Human Resources experience
  • 4+ years of business partner experience
  • Strong working knowledge of California employment law
  • Proficiency with HRIS systems and Microsoft Office Suite
  • Experience working in an international company and/or in the pharmaceutical or manufacturing industry (preferred)
  • Excellent communication and presentation skills (verbal and written)
  • Demonstrated ability to handle confidential and sensitive issues
  • Demonstrated knowledge and experience in counseling, coaching, project management, and employment law
  • Ability to effectively organize, multitask, and work in a fast-paced, deadline driven work environment
  • Ability to communicate in a proactive and solution-focused manner, including keeping management aware of potential issues
  • Detail oriented with the ability to troubleshoot and resolve problems
  • Ability to work independently and manage one’s time
  • Basic computer knowledge, including Microsoft Word, Excel and PowerPoint
  • Preferred certifications: PHR, SHRM-CP, SPHR or SHRM-SCP
Responsibilities
  • Serve as a trusted advisor to leaders and team members, providing guidance on HR policies, procedures, and best practices. Ensure compliance with federal, state and local employment laws, including California-specific requirements (FEHA, CFRA, Wage & Hour, OSHA)
  • Partner with leadership to assess workforce needs and develop strategies including recruitment, onboarding, retention, succession planning, talent and performance management, coaching, documentation, and development planning
  • Foster a positive work environment through proactive collaboration with the leaders and team members. Partner with management to address team member issues and concerns, facilitate fair and consistent resolutions and respond to team member inquiries on HR related matters
  • Support the hiring and selection process by partnering with hiring managers and the Talent Acquisition team on hiring strategies, compliant job descriptions, and offer decisions. Ensure effective onboarding of all new hires.
  • Lead complex employee relations matters, including investigations, coaching, conflict resolution and policy interpretation, ensuring outcomes are compliant, fair and consistent
  • Design and deliver classroom and virtual training programs to promote awareness of HR practices, applicable regulations, and to support leadership and team member growth and engagement.
  • Collaborate with HR colleagues to implement HR programs, policies, and global initiatives across assigned business units.
  • Support the performance management process, including reviews and calibration, to promote consistency, fairness and timely feedback to all team members.
  • Provide guidance on ADA accommodations and the interactive process and manage and track all leaves of absence and workers’ compensation claims.

Bachem provides development and manufacturing of peptides and oligonucleotides for research, clinical development, and commercial products. Its offerings include custom synthesis and scale-up production, analytical testing, and related services across the drug development spectrum. Customers work with Bachem by specifying desired sequences and specifications, after which Bachem designs, synthesizes, and quality-controls the peptides or oligonucleotides and delivers them in appropriate scales and formats. The company differentiates itself through more than five decades of experience, a global footprint with sites in Europe, the US, and Asia, and an integrated set of services spanning discovery support to commercial manufacturing. Its goal is to help pharmaceutical and biotechnology companies advance peptide- and oligonucleotide-based therapies by providing reliable, scalable, and well-supported manufacturing and development capabilities.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Bubendorf, Switzerland

Founded

1971

Simplify Jobs

Simplify's Take

What believers are saying

  • Oligonucleotide market expansion via TIRmed Pharma collaboration for atopic dermatitis.
  • CHF 500 million credit facility enables capacity expansion toward CHF 1B revenue target.
  • New CEO Anne-Kathrin Stoller brings Americas operational expertise and commercial focus.

What critics are saying

  • CEO transition disrupts execution of strategic growth initiatives through 2026.
  • Elevated debt servicing costs from syndicated facility erode 30% EBITDA margin target.
  • Chinese competitors scale oligonucleotide production at 40% lower costs via subsidies.

What makes Bachem unique

  • Leading peptide and oligonucleotide CDMO with 50+ years manufacturing expertise.
  • Integrated GMP capabilities for clinical-stage oligonucleotide therapeutics development.
  • Global footprint across Switzerland, US, and Europe with established pharma relationships.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Bachem who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Company News

Nordic Life Science
Nov 18th, 2025
TIRmed Pharma collaborates with Bachem

TIRmed Pharma collaborates with Bachem. The collaboration includes process development and manufacturing of TIR-01, the active substance in TIRmed's treatment for atopic dermatitis (eczema), and marks an important step towards future clinical trials. As part of its preclinical program, TIRmed Pharma is collaborating with Bachem to establish high-quality production processes for TIR-01, an oligonucleotide-based compound, they describe in a press release. With its expertise in oligonucleotide production, Bachem provides critical expertise for GMP development, ensuring stability, consistency and regulatory compliance for upcoming clinical studies according to the company. "The collaboration with Bachem is an important milestone in the work of taking our drug candidate further towards the clinic," says Leo Holmgren, CEO of TIRmed Pharma. "It gives us access to world-leading manufacturing expertise and strengthens the foundation for being able to offer patients a longer-term treatment alternative," he adds. Learn more about the science behind TIRmed Pharma and its connections to this year's Nobel Prize in Medicine in our latest issue of the magazine - out now!

CHEManager
Oct 31st, 2025
Anne-Kathrin Stoller Becomes New CEO at Bachem

Anne-Kathrin Stoller becomes new CEO at Bachem. Bachem announced today that the Board of Directors has appointed Anne-Kathrin Stoller, the former Head of Bachem Americas and previously the company's CMO for many years, as the new CEO effective january 1, 2026. She succeeds Thomas Meier, who has decided to take on a new challenge outside the company after more than thirty years at Bachem and almost six years as CEO. "Thomas Meier has contributed significantly to Bachem's continued success. Together with his team, he has achieved a capital-efficient and profitable growth. At the same time, Bachem's position as an innovative and reliable partner to the pharmaceutical industry has been further strengthened. We would like to express our sincere thanks to Thomas for his many years of service, his leadership and extraordinary contribution to Bachem," says Kuno Sommer, Chairman of the Board of Directors of Bachem. He continues: "I am very pleased that we have been able to appoint Anne-Kathrin Stoller, an experienced and competent successor from within our own ranks, as the new CEO. Anne-Kathrin has an excellent combination of expertise, leadership skills, and customer focus and, together with her colleagues in the Executive Committee, will continue Bachem's successful course." Thomas Meier, CEO, Bachem, added: "Bachem is a great company and has developed into a leading global, innovation-driven developer and manufacturer of peptides and oligonucleotides in recent years. I have had the privilege of helping to shape and accompany this development in various roles over the past three decades, and I am very grateful for the many enriching experiences I have had at work and the formative encounters with people. Above all, I would like to thank Bachem's employees and customers, as well as my colleagues in the Executive Committee and on the Board of Directors, for their active support and excellent cooperation." Anne-Kathrin Stoller, current Head of Bachem Americas and future CEO, Bachem, commented: "I am delighted to have earned the trust of the Board of Directors and will do everything in my power, together with the members of the Executive Committee and all Bachem employees, to continue our company's impressive success story. Under the leadership of Thomas Meier, Bachem has set the course for the future. I would like to thank him for his collegial support over the past years and everyone at Bachem who works hard every day to ensure that we make an important contribution to human health." Anne-Kathrin Stoller has worked for Bachem since 2006. After holding various management positions, including Head of Business Development & Sales Europe, Chief Marketing Officer and member of the Group Executive Board, she took on the role of Chief Operating Officer Americas in 2022 and is responsible for the company's US business. Anne-Kathrin Stoller studied chemistry in Hanover and Cambridge (UK) and holds a doctorate in bioorganic chemistry from the University of Basel.

Stock Titan
Aug 20th, 2025
Bachem Expands Corporate Executive Committee to Include Chief Operations Officer Role

Bachem (OTC:BCHMY) has announced the appointment of Hans Van Hees as Chief Operations Officer (COO), effective September 1, 2025.

Stock Titan
Jul 24th, 2025
Bachem Shows Strong Growth in the First Half of 2025

Looking ahead, Bachem aims to achieve annual sales exceeding CHF 1 billion and an EBITDA margin over 30% by 2026, supported by significant investments including the new Building K facility and planned expansion in Sisslerfeld.

PharmiWeb.com
Nov 27th, 2024
Green Manufacturing In Pharma: Sustainable Oligonucleotide Production On An Industrial Scale

Oligonucleotides are at the forefront of modern medicine, and have emerged as powerful tools in treating diseases in recent years. Oligonucleotides – short DNA or RNA molecules that host a range of applications in genetic testing, research, and forensics – have seen a marked growth in significance as therapeutics. As their clinical application widens, methods of production must be robust to ensure demand is met. Demand for oligonucleotides in medicines is steadily increasing, with pressing need for an eco-friendly manufacturing process which satisfies green manufacturing standards without compromising yield or process efficiency. Thus, the responsibility lies with manufacturers to ensure end users receive their medications, while striving for sustainable production methods